Related Experiment Video
Updated: Aug 11, 2026
08:40
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
Published on: April 8, 2016
Procoagulant properties of benign and malignant prostatic tissue
A S Adamson1, J L Francis, R O Witherow
1Department of Urology, St Mary's Hospital, London, UK.
British Journal of Urology
|August 1, 1994
Summary
Prostate cancer tissue shows significantly lower factor-X activating procoagulant activity (FXAA) compared to benign tissue. This reduction in FXAA correlates with tumor aggressiveness and may influence prostate cancer growth.
Area of Science:
- Urology
- Oncology
- Biochemistry
Background:
- Prostatic tissue harbors procoagulant activity.
- Factor-X activating procoagulant activity (FXAA) is a key hemostatic enzyme.
- Understanding FXAA in prostate cancer is crucial for disease progression insights.
Purpose of the Study:
- To quantify factor-X activating procoagulant activity (FXAA) in prostatic tissue.
- To compare FXAA levels in prostate cancer versus benign prostatic hypertrophy (BPH).
- To correlate FXAA with established markers of prostate cancer aggressiveness.
Main Methods:
- FXAA was extracted from transurethral resection specimens using cryofragmentation.
- Chromogenic assays were employed to measure enzyme activity.
- Tissue from 50 prostate cancer patients and 36 BPH controls were analyzed.
Main Results:
- FXAA was significantly lower in malignant prostate tissue than in BPH tissue (P < 0.001).
- Reduced FXAA correlated with higher Gleason grade, increased tumor involvement, and advanced bone scan status.
- Antibody inhibition identified the procoagulant as a factor VII/tissue factor complex.
Conclusions:
- Malignant transformation of the prostate is associated with decreased FXAA.
- Reduced FXAA may play a role in prostate tumor growth and metastasis.
- FXAA levels could serve as a biomarker for prostate cancer progression.
